Base de dados : MEDLINE
Pesquisa : D27.505.259 [Categoria DeCS]
Referências encontradas : 88 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 9 ir para página                      

  1 / 88 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Buchpiguel, Carlos Alberto
Chammas, Roger
Texto completo
[PMID]:28196364
[Au] Autor:Camacho X; Machado CL; García MF; Gambini JP; Banchero A; Fernández M; Oddone N; Bertolini Zanatta D; Rosal C; Buchpiguel CA; Chammas R; Riva E; Cabral P
[Ad] Endereço:Departamento de Radiofarmacia, Centro de Investigaciones Nucleares, Facultad de Ciencias, Universidad de la República, Montevideo, Uruguay.
[Ti] Título:Technetium-99m- or Cy7-Labeled Rituximab as an Imaging Agent for Non-Hodgkin Lymphoma.
[So] Source:Oncology;92(4):229-242, 2017.
[Is] ISSN:1423-0232
[Cp] País de publicação:Switzerland
[La] Idioma:eng
[Ab] Resumo:INTRODUCTION: Rituximab was the first monoclonal antibody approved for the treatment of B-cell non-Hodgkin lymphoma (NHL) expressing CD20 antigen. This antibody has also the potential to be used as a specific fluorescent and radiolabel agent for targeting NHL. OBJECTIVE: To radiolabel rituximab with technetium-99m (99mTc) or Cy7 and evaluate both probes as potential imaging agents for NHL. METHODS: Rituximab was derivatized with the trifluoroacetyl hydrazino protected form of succinimidyl ester of HYNIC and radiolabeled with 99mTc. Radiochemical stability and in vitro cell assays were evaluated. Biodistribution and single-photon emission computed tomography/computed tomography (SPECT/CT) were performed. Raji cells were transfected with luciferase for bioluminescent NHL imaging up to 21 days. Rituximab was labeled with Cy7 for in vivo noninvasive fluorescence imaging up to 96 h. RESULTS: Radiolabeling was carried out in a fast, reproducible, easy, and stable way with high radiochemical purity and did not interfere with epitope recognition. Biodistribution and SPECT/CT studies showed high liver and discrete tumor uptake. Bioluminescence and fluorescence studies helped us evaluate rituximab-Cy7 in Raji subcutaneous engraftment in BALB/c nude mice. CONCLUSIONS: Our results support the potential use of rituximab labeled either with 99mTc or Cy7 as a molecular imaging tool for staging, restaging, and guiding surgical excision of tumors, which merits further evaluation.
[Mh] Termos MeSH primário: Carbocianinas
Linfoma não Hodgkin/diagnóstico por imagem
Imagem Molecular/métodos
Rituximab
Tecnécio
[Mh] Termos MeSH secundário: Animais
Antígenos CD20/metabolismo
Carbocianinas/farmacocinética
Linhagem Celular Tumoral
Usos Diagnósticos de Compostos Químicos
Feminino
Seres Humanos
Camundongos Endogâmicos BALB C
Compostos Radiofarmacêuticos/metabolismo
Compostos Radiofarmacêuticos/farmacocinética
Rituximab/química
Rituximab/metabolismo
Rituximab/farmacocinética
Tomografia Computadorizada com Tomografia Computadorizada de Emissão de Fóton Único/métodos
Tecnécio/farmacocinética
Distribuição Tecidual
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antigens, CD20); 0 (Carbocyanines); 0 (Diagnostic Uses of Chemicals); 0 (Radiopharmaceuticals); 0 (indotricarbocyanine); 4F4X42SYQ6 (Rituximab); 7440-26-8 (Technetium)
[Em] Mês de entrada:1704
[Cu] Atualização por classe:170410
[Lr] Data última revisão:
170410
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170215
[St] Status:MEDLINE
[do] DOI:10.1159/000452419


  2 / 88 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28053522
[Au] Autor:Löndahl J; Jakobsson JK; Broday DM; Aaltonen HL; Wollmer P
[Ad] Endereço:Division of Ergonomics and Aerosol Technology (EAT), Department of Design Sciences; NanoLund, Lund University, Lund, Sweden.
[Ti] Título:Do nanoparticles provide a new opportunity for diagnosis of distal airspace disease?
[So] Source:Int J Nanomedicine;12:41-51, 2017.
[Is] ISSN:1178-2013
[Cp] País de publicação:New Zealand
[La] Idioma:eng
[Ab] Resumo:There is a need for efficient techniques to assess abnormalities in the peripheral regions of the lungs, for example, for diagnosis of pulmonary emphysema. Considerable scientific efforts have been directed toward measuring lung morphology by studying recovery of inhaled micron-sized aerosol particles (0.4-1.5 µm). In contrast, it is suggested that the recovery of inhaled airborne nanoparticles may be more useful for diagnosis. The objective of this work is to provide a theoretical background for the use of nanoparticles in measuring lung morphology and to assess their applicability based on a review of the literature. Using nanoparticles for studying distal airspace dimensions is shown to have several advantages over other aerosol-based methods. 1) Nanoparticles deposit almost exclusively by diffusion, which allows a simpler breathing maneuver with minor artifacts from particle losses in the oropharyngeal and upper airways. 2) A higher breathing flow rate can be utilized, making it possible to rapidly inhale from residual volume to total lung capacity (TLC), thereby eliminating the need to determine the TLC before measurement. 3) Recent studies indicate better penetration of nanoparticles than micron-sized particles into poorly ventilated and diseased regions of the lungs; thus, a stronger signal from the abnormal parts is expected. 4) Changes in airspace dimensions have a larger impact on the recovery of nanoparticles. Compared to current diagnostic techniques with high specificity for morphometric changes of the lungs, computed tomography and magnetic resonance imaging with hyperpolarized gases, an aerosol-based method is likely to be less time consuming, considerably cheaper, simpler to use, and easier to interpret (providing a single value rather than an image that has to be analyzed). Compared to diagnosis by carbon monoxide ( ), the uptake of nanoparticles in the lung is not affected by blood flow, hemoglobin concentration or alterations of the alveolar membranes, but relies only on lung morphology.
[Mh] Termos MeSH primário: Usos Diagnósticos de Compostos Químicos
Medidas de Volume Pulmonar/métodos
Nanopartículas
[Mh] Termos MeSH secundário: Administração por Inalação
Aerossóis
Difusão
Seres Humanos
Pulmão/patologia
Imagem por Ressonância Magnética
Tamanho da Partícula
Doença Pulmonar Obstrutiva Crônica/diagnóstico
Doença Pulmonar Obstrutiva Crônica/fisiopatologia
Respiração
Sensibilidade e Especificidade
Tomografia Computadorizada por Raios X
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Aerosols); 0 (Diagnostic Uses of Chemicals)
[Em] Mês de entrada:1702
[Cu] Atualização por classe:170224
[Lr] Data última revisão:
170224
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170106
[St] Status:MEDLINE
[do] DOI:10.2147/IJN.S121369


  3 / 88 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28025143
[Au] Autor:Chatterjee S; Lesniak WG; Miller MS; Lisok A; Sikorska E; Wharram B; Kumar D; Gabrielson M; Pomper MG; Gabelli SB; Nimmagadda S
[Ad] Endereço:Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University, Baltimore, MD, USA.
[Ti] Título:Rapid PD-L1 detection in tumors with PET using a highly specific peptide.
[So] Source:Biochem Biophys Res Commun;483(1):258-263, 2017 Jan 29.
[Is] ISSN:1090-2104
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Molecular imaging can report on the status of the tumor immune microenvironment and guide immunotherapeutic strategies to enhance the efficacy of immune modulation therapies. Imaging agents that can rapidly report on targets of immunomodulatory therapies are few. The programmed death ligand 1 (PD-L1) is an immune checkpoint protein over-expressed in several cancers and contributes to tumor immune suppression. Tumor PD-L1 expression is indicative of tumor response to PD-1 and PD-L1 targeted therapies. Herein, we report a highly specific peptide-based positron emission tomography (PET) imaging agent for PD-L1. We assessed the binding modes of the peptide WL12 to PD-L1 by docking studies, developed a copper-64 labeled WL12 ([ Cu]WL12), and performed its evaluation in vitro, and in vivo by PET imaging, biodistribution and blocking studies. Our results show that [ Cu]WL12 can be used to detect tumor PD-L1 expression specifically and soon after injection of the radiotracer, to fit within the standard clinical workflow of imaging within 60 min of administration.
[Mh] Termos MeSH primário: Antígeno B7-H1/análise
Neoplasias/metabolismo
Peptídeos/metabolismo
Peptídeos/farmacocinética
Tomografia por Emissão de Pósitrons/métodos
[Mh] Termos MeSH secundário: Animais
Antígeno B7-H1/metabolismo
Células CHO
Radioisótopos de Cobre/administração & dosagem
Radioisótopos de Cobre/farmacocinética
Cricetulus
Usos Diagnósticos de Compostos Químicos
Feminino
Seres Humanos
Camundongos SCID
Simulação de Acoplamento Molecular
Neoplasias/diagnóstico por imagem
Peptídeos/administração & dosagem
Receptor de Morte Celular Programada 1/metabolismo
Distribuição Tecidual
Ensaios Antitumorais Modelo de Xenoenxerto
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (B7-H1 Antigen); 0 (CD274 protein, human); 0 (Copper Radioisotopes); 0 (Diagnostic Uses of Chemicals); 0 (PDCD1 protein, human); 0 (Peptides); 0 (Programmed Cell Death 1 Receptor)
[Em] Mês de entrada:1706
[Cu] Atualização por classe:171116
[Lr] Data última revisão:
171116
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161228
[St] Status:MEDLINE


  4 / 88 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
PubMed Central Texto completo
Texto completo
[PMID]:27574424
[Au] Autor:Fan X; Guo Y; Wang L; Xiong X; Zhu L; Fang K
[Ad] Endereço:Department of Ultrasound, Southwest Hospital, Third Military Medical University, Chongqing, People's Republic of China.
[Ti] Título:Diagnosis of prostate cancer using anti-PSMA aptamer A10-3.2-oriented lipid nanobubbles.
[So] Source:Int J Nanomedicine;11:3939-50, 2016.
[Is] ISSN:1178-2013
[Cp] País de publicação:New Zealand
[La] Idioma:eng
[Ab] Resumo:In this study, the lipid targeted nanobubble carrying the A10-3.2 aptamer against prostate specific membrane antigen was fabricated, and its effect in the ultrasound imaging of prostate cancer was investigated. Materials including 2-dipalmitoyl-sn-glycero-3-phosphocholine, 1,2-dipalmitoyl-sn-glycero-3-phosphatidic acid, 1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine, 1,2-dipalmitoyl-sn-glycero-3-phosphoglycerol, carboxyl-modified 1,2-distearoyl-sn-glycero-3-phosphoethanolamine, and polyethyleneglycol-2000 were for mechanical oscillation, and nanobubbles were obtained through the centrifugal flotation method. After mice were injected with nanobubbles, abdominal color Doppler blood flow imaging significantly improved. Through left ventricular perfusion with normal saline to empty the circulating nanobubbles, nanobubbles still existed in tumor tissue sections, which demonstrated that nanobubbles could enter tissue spaces via the permeability and retention effect. Fluorinated A10-3.2 aptamers obtained by chemical synthesis had good specificity for PSMA-positive cells, and were linked with carboxyl-modified 1,2-distearoyl-sn-glycero-3-phosphoethanolamine lipid molecules from the outer shell of nanobubbles via amide reaction to construct targeted nanobubbles. Gel electrophoresis and immunofluorescence confirmed that targeted nanobubbles were fabricated successfully. Next, targeted nanobubbles could bind with PSMA-positive cells (C4-2 cells), while not with PSMA-negative cells (PC-3 cells), using in vitro binding experiments and flow cytometry at the cellular level. Finally, C4-2 and PC-3 xenografts in mice were used to observe changes in parameters of targeted and non-targeted nanobubbles in the contrast-enhanced ultrasound mode, and the distribution of Cy5.5-labeled targeted nanobubbles in fluorescent imaging of live small animals. Comparison of ultrasound indicators between targeted and non-targeted nanobubbles in C4-2 xenografts showed that they had similar peak times (P>0.05), while the peak intensity, half time of peak intensity, and area under the curve of ½ peak intensity were significantly different (P<0.05). In PC-3 xenografts, there were no differences in these four indicators. Fluorescent imaging indicated that targeted nanobubbles had an aggregation ability in C4-2 xenograft tumors. In conclusion, targeted nanobubbles carrying the anti-PSMA A10-3.2 aptamer have a targeted imaging effect in prostate cancer.
[Mh] Termos MeSH primário: Antígenos de Superfície/metabolismo
Aptâmeros de Nucleotídeos/química
Glutamato Carboxipeptidase II/metabolismo
Nanoestruturas/administração & dosagem
Neoplasias da Próstata/diagnóstico por imagem
Ultrassonografia/métodos
[Mh] Termos MeSH secundário: Animais
Antígenos de Superfície/genética
Carbocianinas/farmacocinética
Linhagem Celular Tumoral
Meios de Contraste/farmacocinética
Usos Diagnósticos de Compostos Químicos
Glutamato Carboxipeptidase II/genética
Seres Humanos
Lipídeos/química
Masculino
Camundongos Nus
Nanoestruturas/química
Tamanho da Partícula
Polietilenoglicóis/química
Ultrassonografia Doppler em Cores/métodos
Ensaios Antitumorais Modelo de Xenoenxerto
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antigens, Surface); 0 (Aptamers, Nucleotide); 0 (CY5.5 cyanine dye); 0 (Carbocyanines); 0 (Contrast Media); 0 (Diagnostic Uses of Chemicals); 0 (Lipids); 30IQX730WE (Polyethylene Glycols); EC 3.4.17.21 (Glutamate Carboxypeptidase II); EC 3.4.17.21 (glutamate carboxypeptidase II, human)
[Em] Mês de entrada:1702
[Cu] Atualização por classe:170817
[Lr] Data última revisão:
170817
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160831
[St] Status:MEDLINE
[do] DOI:10.2147/IJN.S112951


  5 / 88 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
PubMed Central Texto completo
Texto completo
[PMID]:26730187
[Au] Autor:Kalomiraki M; Thermos K; Chaniotakis NA
[Ad] Endereço:Laboratory of Analytical Chemistry, Department of Chemistry, University of Crete Voutes, Heraklion, Greece.
[Ti] Título:Dendrimers as tunable vectors of drug delivery systems and biomedical and ocular applications.
[So] Source:Int J Nanomedicine;11:1-12, 2016.
[Is] ISSN:1178-2013
[Cp] País de publicação:New Zealand
[La] Idioma:eng
[Ab] Resumo:Dendrimers are large polymeric structures with nanosize dimensions (1-10 nm) and unique physicochemical properties. The major advantage of dendrimers compared with linear polymers is their spherical-shaped structure. During synthesis, the size and shape of the dendrimer can be customized and controlled, so the finished macromolecule will have a specific "architecture" and terminal groups. These characteristics will determine its suitability for drug delivery, diagnostic imaging, and as a genetic material carrier. This review will focus initially on the unique properties of dendrimers and their use in biomedical applications, as antibacterial, antitumor, and diagnostic agents. Subsequently, emphasis will be given to their use in drug delivery for ocular diseases.
[Mh] Termos MeSH primário: Dendrímeros/administração & dosagem
Dendrímeros/farmacologia
Sistemas de Liberação de Medicamentos/métodos
Nanomedicina/métodos
[Mh] Termos MeSH secundário: Administração Oral
Antibacterianos/administração & dosagem
Antibacterianos/química
Antineoplásicos/administração & dosagem
Antineoplásicos/química
Dendrímeros/química
Usos Diagnósticos de Compostos Químicos
Interações Medicamentosas
Oftalmopatias/tratamento farmacológico
Técnicas de Transferência de Genes
Seres Humanos
Polímeros/química
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Anti-Bacterial Agents); 0 (Antineoplastic Agents); 0 (Dendrimers); 0 (Diagnostic Uses of Chemicals); 0 (Polymers)
[Em] Mês de entrada:1609
[Cu] Atualização por classe:170220
[Lr] Data última revisão:
170220
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160106
[St] Status:MEDLINE
[do] DOI:10.2147/IJN.S93069


  6 / 88 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:26562545
[Au] Autor:Wagner S; Scheunemann M; Dipper K; Egerland U; Hoefgen N; Steinbach J; Brust P
[Ad] Endereço:Helmholtz-Zentrum Dresden - Rossendorf, Institute of Radiopharmaceutical Cancer Research, Research Site Leipzig, Dept. of Neuroradiopharmaceuticals, Permoserstrasse 15, 04318 Leipzig, Germany. Electronic address: s.wagner@hzdr.de.
[Ti] Título:Development of highly potent phosphodiesterase 10A (PDE10A) inhibitors: Synthesis and in vitro evaluation of 1,8-dipyridinyl- and 1-pyridinyl-substituted imidazo[1,5-a]quinoxalines.
[So] Source:Eur J Med Chem;107:97-108, 2016 Jan 01.
[Is] ISSN:1768-3254
[Cp] País de publicação:France
[La] Idioma:eng
[Ab] Resumo:Herein we report the synthesis of fluorinated inhibitors of phosphodiesterase 10A (PDE10A) which can be used potentially as lead structure for the development of a (18)F-labeled PDE10A imaging agent for positron emission tomography. The use of ortho-fluoropyridines as residues could potentially enable the introduction of (18)F through nucleophilic substitution for radiolabeling purposes. 2-Fluoropyridines are introduced by a Suzuki coupling at different positions of the molecule. The reference compounds, 1,8-dipyridinylimidazo[1,5-a]quinoxalines and 1-pyridinylimidazo[1,5-a]quinoxalines, show inhibitory potencies at best in the subnanomolar range and selectivity factors greater than 38 against other PDE's. 1,8-Dipyridinylimidazo[1,5-a]quinoxalines are more potent inhibitors than 1-pyridinylimidazo[1,5-a]quinoxalines. Using 2-fluoro-3-pyridinyl as residue provided the most potent inhibitors 16 (IC50 = 0.12 nM), 17 (IC50 = 0.048 nM) and 32 (IC50 = 0.037 nM).
[Mh] Termos MeSH primário: Inibidores de Fosfodiesterase/química
Inibidores de Fosfodiesterase/farmacologia
Diester Fosfórico Hidrolases/metabolismo
Quinoxalinas/química
[Mh] Termos MeSH secundário: Bromo/química
Técnicas de Química Sintética
Usos Diagnósticos de Compostos Químicos
Avaliação Pré-Clínica de Medicamentos
Seres Humanos
Concentração Inibidora 50
Tomografia por Emissão de Pósitrons/métodos
Relação Estrutura-Atividade
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Diagnostic Uses of Chemicals); 0 (Phosphodiesterase Inhibitors); 0 (Quinoxalines); EC 3.1.4.- (PDE10A protein, human); EC 3.1.4.- (Phosphoric Diester Hydrolases); SBV4XY874G (Bromine)
[Em] Mês de entrada:1609
[Cu] Atualização por classe:151208
[Lr] Data última revisão:
151208
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:151113
[St] Status:MEDLINE


  7 / 88 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:26223472
[Au] Autor:Yamamichi N; Hirano C; Takahashi Y; Minatsuki C; Nakayama C; Matsuda R; Shimamoto T; Takeuchi C; Kodashima S; Ono S; Tsuji Y; Fujishiro M; Wada R; Mitsushima T; Koike K
[Ad] Endereço:Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, 7-3-1, Hongo, Bunkyo-ku, Tokyo, Japan. nyamamic-tky@umin.ac.jp.
[Ti] Título:Comparative analysis of upper gastrointestinal endoscopy, double-contrast upper gastrointestinal barium X-ray radiography, and the titer of serum anti-Helicobacter pylori IgG focusing on the diagnosis of atrophic gastritis.
[So] Source:Gastric Cancer;19(2):670-5, 2016 Apr.
[Is] ISSN:1436-3305
[Cp] País de publicação:Japan
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Upper gastrointestinal endoscopy (UGI-ES) and double-contrast upper gastrointestinal barium X-ray radiography (UGI-XR) are two major image-based methods to diagnose atrophic gastritis, which is mostly induced by Helicobacter pylori infection. However, there have been few studies directly comparing them. METHODS: Atrophic gastritis was evaluated using the data of 962 healthy subjects who underwent UGI-ES and UGI-XR within 1 year. RESULTS AND CONCLUSION: Based on UGI-ES and UGI-XR, 602 subjects did not have atrophic gastritis and 254 subjects did have it. Considering UGI-ES-based atrophic gastritis as the standard, sensitivity and specificity of UGI-XR-based atrophic gastritis were 92.0 % (254/276) and 92.8 % (602/649), respectively. The seven-grade Kimura-Takemoto classification of UGI-ES-based atrophic gastritis showed a strong and significant association with the four-grade UGI-XR-based atrophic gastritis. Sensitivity and specificity of serum anti-Helicobacter pylori IgG to detect UGI-ES/UGI-XR-based atrophic gastritis were 89.4 % (227/254) and 99.8 % (601/602), indicating that atrophic gastritis can be overlooked according to serum anti-Helicobacter pylori IgG alone.
[Mh] Termos MeSH primário: Endoscopia Gastrointestinal/métodos
Gastrite Atrófica/diagnóstico por imagem
Infecções por Helicobacter/sangue
Imunoglobulina G/sangue
Radiografia Abdominal/métodos
[Mh] Termos MeSH secundário: Adulto
Idoso
Bário
Meios de Contraste
Usos Diagnósticos de Compostos Químicos
Gastrite Atrófica/imunologia
Gastrite Atrófica/microbiologia
Trato Gastrointestinal/diagnóstico por imagem
Infecções por Helicobacter/complicações
Helicobacter pylori/imunologia
Seres Humanos
Masculino
Meia-Idade
Sensibilidade e Especificidade
Raios X
Adulto Jovem
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Contrast Media); 0 (Diagnostic Uses of Chemicals); 0 (Immunoglobulin G); 24GP945V5T (Barium)
[Em] Mês de entrada:1612
[Cu] Atualização por classe:171013
[Lr] Data última revisão:
171013
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:150731
[St] Status:MEDLINE
[do] DOI:10.1007/s10120-015-0515-y


  8 / 88 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:26995877
[Au] Autor:Watanabe A
[Ti] Título:[Companion Diagnostics for Solid Tumors].
[So] Source:Rinsho Byori;63(11):1310-5, 2015 Nov.
[Is] ISSN:0047-1860
[Cp] País de publicação:Japan
[La] Idioma:jpn
[Ab] Resumo:Companion diagnostics (CoDx) will likely continue to rapidly increase in number and application to disease areas including solid tumors, for example EGFR for gefitinib and ALK fusion gene for crizotinib in non-small-cell lung cancer; KRAS against the use of cetuximab and panitumumab in colorectal cancer; HER2 for trastuzumab in breast cancer. CoDx are an indispensable part of personalized medicine and pharmacogenomics. In CoDx development, there are still many challenges, such as the business model promoting cooperation between diagnostics and pharmaceutical companies, and also the regulations related to CoDx. The FDA notice on the development of CoDx in 2011 recommended the co-development of a new drug and CoDx as the best practice, and the Ministry of Health, Labour and Welfare in Japan also issued a statement in 2013. In addition, the recent discovery of many novel variants in the DNA sequence, advances in sequencing and genomic technology, and improved analytic methods have enabled the impact of germline and somatic mutations to be determined using multiplex diagnosis. The complex challenges to develop CoDx necessitate a close collaboration among academic institutions, regulatory authorities, and pharmaceutical companies. [Review].
[Mh] Termos MeSH primário: Neoplasias da Mama/diagnóstico
Neoplasias do Colo/diagnóstico
Usos Diagnósticos de Compostos Químicos
Neoplasias Pulmonares/diagnóstico
Técnicas de Diagnóstico Molecular
[Mh] Termos MeSH secundário: Biomarcadores Tumorais
Neoplasias da Mama/tratamento farmacológico
Neoplasias da Mama/genética
Cetuximab/uso terapêutico
Neoplasias do Colo/tratamento farmacológico
Neoplasias do Colo/genética
Descoberta de Drogas
Fusão Gênica/genética
Guias como Assunto
Seres Humanos
Neoplasias Pulmonares/tratamento farmacológico
Neoplasias Pulmonares/genética
Terapia de Alvo Molecular
Farmacogenética
Medicina de Precisão
Proteínas Proto-Oncogênicas p21(ras)/genética
Pirazóis/uso terapêutico
Piridinas/uso terapêutico
Quinazolinas/uso terapêutico
Receptores Proteína Tirosina Quinases/genética
Receptor do Fator de Crescimento Epidérmico
Receptor ErbB-2/genética
Trastuzumab/uso terapêutico
[Pt] Tipo de publicação:ENGLISH ABSTRACT; JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Biomarkers, Tumor); 0 (Diagnostic Uses of Chemicals); 0 (KRAS protein, human); 0 (Pyrazoles); 0 (Pyridines); 0 (Quinazolines); 53AH36668S (crizotinib); EC 2.7.10.1 (ERBB2 protein, human); EC 2.7.10.1 (Receptor Protein-Tyrosine Kinases); EC 2.7.10.1 (Receptor, Epidermal Growth Factor); EC 2.7.10.1 (Receptor, ErbB-2); EC 2.7.10.1 (anaplastic lymphoma kinase); EC 3.6.5.2 (Proto-Oncogene Proteins p21(ras)); P188ANX8CK (Trastuzumab); PQX0D8J21J (Cetuximab); S65743JHBS (gefitinib)
[Em] Mês de entrada:1604
[Cu] Atualização por classe:160321
[Lr] Data última revisão:
160321
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160322
[St] Status:MEDLINE


  9 / 88 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:26736713
[Au] Autor:Demosthenous P; Georgiou J
[Ti] Título:An ingestible, NIR-fluorometric, cancer-screening capsule.
[So] Source:Conf Proc IEEE Eng Med Biol Soc;2015:2143-6, 2015.
[Is] ISSN:1557-170X
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Asymptomatic, early-stage, cancer detection is a problem in the small intestine, that is largely inaccessible. This paper presents a cost-effective screening capsule prototype, which is able to detect infrared (IR) fluorescence emitted by indocyanine green (ICG) fluorophore dye. The presented mixed-signal system has a small size, consumes little power and works as a high-sensitivity fluorometer that records fluorescence levels throughout the small intestine, rather than collecting images that need labour intensive video analysis. Ex-vivo experiments, on ICG-impregnated swine intestine, have shown that the prototype system is able to detect low concentrations of ICG in the nanomolar and micromolar region, which is required to detect early cancer in the small intestine.
[Mh] Termos MeSH primário: Cápsulas/administração & dosagem
Fluorometria/métodos
Verde de Indocianina/análise
Neoplasias Intestinais/diagnóstico
[Mh] Termos MeSH secundário: Animais
Cápsulas/química
Usos Diagnósticos de Compostos Químicos
Detecção Precoce de Câncer/métodos
Desenho de Equipamento
Fluorescência
Corantes Fluorescentes/análise
Fluorometria/instrumentação
Intestino Delgado/patologia
Lasers Semicondutores
Suínos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Capsules); 0 (Diagnostic Uses of Chemicals); 0 (Fluorescent Dyes); IX6J1063HV (Indocyanine Green)
[Em] Mês de entrada:1609
[Cu] Atualização por classe:160107
[Lr] Data última revisão:
160107
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160107
[St] Status:MEDLINE
[do] DOI:10.1109/EMBC.2015.7318813


  10 / 88 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
[PMID]:26702534
[Au] Autor:Lei F; Wang G; Zhao D; Li T; Song X; Shang Q; Cui H; Li J; Qiu B; Gong J
[Ad] Endereço:E-mail: gjy-sd@163.com.
[Ti] Título:[Application of iodine dye used in assessment of early post-operative esophageal lesions].
[So] Source:Zhonghua Bing Li Xue Za Zhi;44(10):741-2, 2015 Oct.
[Is] ISSN:0529-5807
[Cp] País de publicação:China
[La] Idioma:chi
[Mh] Termos MeSH primário: Corantes
Neoplasias Esofágicas/diagnóstico
Esôfago/patologia
Iodo
[Mh] Termos MeSH secundário: Usos Diagnósticos de Compostos Químicos
Esofagoscopia
Seres Humanos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Coloring Agents); 0 (Diagnostic Uses of Chemicals); 9679TC07X4 (Iodine)
[Em] Mês de entrada:1602
[Cu] Atualização por classe:160818
[Lr] Data última revisão:
160818
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:151226
[St] Status:MEDLINE



página 1 de 9 ir para página                      
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde